Biogen

Biogen

Yahoo Finance • 8 days ago

Biogen Swings Back to Growth as Stock Momentum Could Continue, RBC Says

Biogen (BIIB) has swung back to growth as shown by its solid Q3 results, RBC analysts wrote in a not PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 8 days ago

Alphabet downgraded, eBay upgraded: Wall Street's top analyst calls

Alphabet downgraded, eBay upgraded: Wall Street's top analyst calls The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled b... Full story

Yahoo Finance • 8 days ago

What to expect from Regeneron’s (REGN) Q3 earnings

What to expect from Regeneron's (REGN) Q3 earnings Biotech company Regeneron (NASDAQ:REGN) will be announcing earnings results tomorrow before market hours. Here's what investors should know. Regeneron beat analysts' revenue expectations... Full story

Yahoo Finance • 8 days ago

Biogen (BIIB) Stock Price Tracks Q3 Results Through Loss And Cash Flow

Biogen shareholders woke up to a pullback. The stock closed at US$244.05, down 3.4% from the prior session, even though Q3 2026 revenue reached US$2.8b with double digit year on year growth and free cash flow hit US$600m. That gap between... Full story

Yahoo Finance • 9 days ago

Biogen beats Q3 estimates, raises guidance floor on growth

Investing.com -- Biogen Inc (NASDAQ:BIIB) on Wednesday reported third quarter adjusted earnings per share of $2.62, surpassing the analyst consensus of $2.02 by $0.60. Revenue reached $2.8 billion, exceeding the $2.64 billion estimate and... Full story

Yahoo Finance • 9 days ago

Sales of Leqembi® totaled 32.2 billion yen in the third quarter 2026

STOCKHOLM, October 28, 2026 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai today published the preliminary global revenue for Leqembi for the third quarter 2026, in conjunction with their partner Biogen's th... Full story

Yahoo Finance • 9 days ago

Biogen Has 'Returned To Growth,' Says CEO — What To Know About Its Report

Biogen crushed third-quarter expectations early Tuesday, helped by its suite of newer products and leading to a guidance boost. Continue Reading... Full story

Yahoo Finance • 9 days ago

Biogen Crushes Earnings Estimates. As Old Blockbusters Fade, New Bets Pick Up the Slack.

Biogen is leaning on newer drugs, including recently acquired assets, as its multiple sclerosis franchise faces ongoing competition. Continue Reading... Full story

Yahoo Finance • 10 days ago

Biogen (BIIB) Nears Earnings As Investors Ask If The Stock Is Already Fully Valued

Biogen (BIIB) heads into a key moment this week, with the biotech group set to report quarterly earnings before the market opens on Wednesday, a focal point for current sentiment. Recent price action has been strong. Biogen's 1 day share... Full story

Yahoo Finance • 10 days ago

Biogen (BIIB) Stock May Be 45% Undervalued Despite Fresh Kidney Data

Biogen has delivered a strong run over the past year, and the key issue for you now is whether the current share price lines up with the cash the business is expected to generate. After a move like this, the question is how much of Biogen'... Full story

Yahoo Finance • 10 days ago

Kos Biotechnology Partners Announces Strategic Investment in Golden Age Health to Accelerate Global Access to Rare Disease Therapies

Golden Age Health is co-founded and chaired by Michel Vounatsos, former Biogen CEO and Merck President NEW YORK and ATHENS, Greece and SINGAPORE, Oct. 26, 2026 /PRNewswire/ -- Kos Biotechnology Partners ("Kos"), a global life sciences inv... Full story

Yahoo Finance • 11 days ago

Google, Microsoft, Amazon, and the Fed step up to a skittish market: What to watch this week

The first week of Big Tech earnings looked promising — until Thursday hit. After SpaceX (SPCX), Meta (META), and Tesla (TSLA) opened their books without signaling ballooning spending next year, the reality that longer-term projects would,... Full story

Yahoo Finance • 12 days ago

Earnings Week Ahead: MSFT, GOOGL, AMZN, XOM, BA, VZ, and more

[Rolled newspaper with the headline Quarterly Results] Zerbor Another heavyweight earnings week is ahead, with results from Big Tech, energy giants, chipmakers, financial services, healthcare, and industrial leaders set to offer a broad r... Full story

Yahoo Finance • 17 days ago

RBC Capital names top healthcare stocks as sector upgraded to overweight

Investing.com -- RBC Capital has upgraded the Healthcare sector to Overweight from Market Weight, identifying 11 high-conviction stock ideas across therapeutics and non-therapeutics segments. The upgrade is supported by improving flows, po... Full story

Yahoo Finance • 21 days ago

Another Biotech IPO Pops on Rough Day for Broader Market

It's another risk-off day for the broader market, with tech taking another tumble, thanks to a continued slide for semiconductor stocks. Continue Reading... Full story

Yahoo Finance • 24 days ago

Phanes Therapeutics to participate in Longwood Healthcare Leaders Boston CEO, November 2-3, 2026

SAN DIEGO, Oct. 13, 2026 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), a clinical-stage biotech company focused on innovative drug discovery and development in immuno-oncology (IO), announced that Ming Wang (CEO) will participate in... Full story

Yahoo Finance • 24 days ago

Biogen (BIIB) vs Amgen (AMGN) and Gilead (GILD): Which Big Pharma Stock is a Better Buy?

Biogen Inc. (NASDAQ:BIIB) closed at $225.71 on October 9. The stock has returned 30.5% during the last six months, compared to a 24.3% return for the Insider Monkey Billionaire Index and 15.1% for the State Street SPDR S&P 500 ETF Trust.... Full story

Yahoo Finance • 24 days ago

Biogen (BIIB) Stock Is Up, What You Need To Know

Biogen (BIIB) Stock Is Up, What You Need To Know What Happened? Shares of biotech company Biogen (NASDAQ:BIIB) jumped 3.5% in the pre-market session after JPMorgan upgraded the stock to Overweight from Neutral with a $300 price target, r... Full story

Yahoo Finance • 24 days ago

Sector Update: Healthcare Stocks Rise Late Afternoon

Healthcare stocks rose late Monday afternoon, with the NYSE Healthcare Index and the State Street He PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 25 days ago

Biogen (BIIB) Could Be 5% Undervalued After 52 Week Lupus Data

Biogen (BIIB) is back in focus after releasing 52 week Phase 2 data for litifilimab in cutaneous lupus erythematosus, reporting sustained improvements in skin activity and a safety profile described as consistent with earlier studies. For... Full story